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further define the chronotherapy strategy of it in leukemia, we compared the mortality rates,
LD50s, biochemical parameters, histological changes and organ indexes of mice treated with
clofarabine at various doses and time points. Plasma clofarabine levels and pharmacokinetic
parameters were monitored continuously for up to 8 hours after the single intravenous admin-
istration of 20 mg/kg at 12:00 noon and 12:00 midnight by high performance liquid chromatog-
raphy (HPLC)-UV method. Clofarabine toxicity in all groups fluctuated in accordance with
circadian rhythms in vivo. The toxicity of clofarabine in mice in the rest phase was more severe
than the active one, indicated by more severe liver damage, immunodepression, higher mor-
tality rate, and lower LD50. No significant pharmacokinetic parameter changes were observed
between the night and daytime treatment groups. These findings suggest the dosing-time
dependent toxicity of clofarabine synchronizes with the circadian rhythm of mice, which might
provide new therapeutic strategies in further clinical application.
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Clofarabine, a second-generation nucleotide analogue
developed in the late 1980s [1], has been used for the
treatment of acute leukemia. It is a hybrid of cladribine and
fludarabine, and possesses many advantages over the pro-
totype drugs. It is lower in neurotoxicity, more stable in
acidic solution and less susceptible to bacterial cleavage. All
these characteristics promise better oral bioavailability and
clinical safety [2]. Although originally used as a hematologi-
cal malignancies curing agent, it is also efficient on many
other solid tumors and has good therapeutic outcomes in
elderly patients [3]. Available evidence suggests clofarabine
inhibits tumor cell growth mainly via the inhibition of DNA
synthesis, which eventually leads to apoptosis of cells [4e6],
but also exerts cytotoxicity on normal cells. On one hand,
clofarabine suppresses tumor cells in the rapid proliferative
and static phases [4e5], on the other hand, it is indeed
hazardous to the organs and body of humankind.
Efficacy and toxicity of drugs are largely affected by the
circadian rhythm in vivo [7]. Thus, it provides us with a new
strategy for drug therapies with narrow efficacyetoxicity
dosage ratio, like most chemotherapy medicines. The
optimal chronotherapy will augment efficacy and minimize
toxicity of antitumor agents [8]. More than 40 available
clinical chemotherapy drugs have been validated with
obvious chrono-effects in rodents and humans [9e10].
Under a fixed delivery schedule, the tolerability of some
conventional chemotherapy agents may rise by fivefold as
compared with constant dosing-time regimen [11]. Another
promising finding was noticed in independent trials, that is,
the timing of best drug tolerability usually fits to best ef-
ficacy [12]. Therefore, research on the chrono-effects of
drugs, especially for the toxic antitumor drugs, is urgent
and meaningful, and the relevant findings will benefit
clinical practice in the near future.
As a new generation antimetabolism tumor inhibitor,
clofarabine is characterized by high stability and low
toxicity on many tumors. However, clofarabine is usually
distributed in many organs and cells, which certainly causes
systematic toxicity, and sometimes the side effects are
fatal. Our primary research indicated that the toxicity of
clofarabine varied in the 24-hour period of 1 day, and
optimal dosing-time of it may alleviate the instinct toxicity.
However, there is no sufficient evidence to support this
claim. Therefore, in this study, we observed the diurnal
fluctuation of toxicity of clofarabine in 24 hours. We
attempted to find out the relationship between toxicity and
pharmacokinetic circadian rhythms of clofarabine in
experimental animals, which might provide new chro-
nochemotherapy regimen in future.
Experiments
Animal and reagents
Kunming mice (18e22 g, with equal numbers of male and
female mice), were bought from Nanjing Qinglongshan Lab-
oratory Animal Center (Certificate No.: SCXK 20080033). All
these animals were housed individually in a strict 12-hour
light/dark cycle and temperature-controlled (25  2C)environment with pelleted food and water ad libitum, and
fed for 7 days to get used to the artificial diurnal variation
prior to assays. This study was approved by the Animal Care
and Use Committee ofWannanMedical College (Approval No.
of Animal Care: WNYXY 2013-0284), and all the studies were
conducted in accordancewith the Guide for the Care and Use
of Laboratory Animals (US National Research Council 2011).
Clofarabinewas supplied byA-TuoChemical Co. Ltd (Nanjing,
China). Aminoleucine transferase (ALT), aspartate amino-
transferase (AST), creatinine (Cr) and blood urea nitrogen
(BUN) quantitative determination kits were provided by
Jianchen Biological Engineering Institute (Nanjing, China).
Acute toxicity assay
Mice were randomly divided into six groups (20 mice each).
The different groups received intraperitoneal injections of
clofarabine at the dose of 330 mg/kg at 8:00 AM, 12:00 noon,
4:00 PM, 8:00 PM, 12:00 midnight and 4:00 AM, respectively,
each day. The treatments lasted for 7 days. After the first
administration, the treated mice were observed continu-
ously for abnormal reactions and mortality until the end of
the assay. The circadian rhythm of acute toxicity of clo-
farabine at the same dose was analyzed using an observa-
tion based on the cosinor-based rhythmometry method [13].
Another 80 mice were randomly divided into four groups
(20 mice each), and injected intraperitoneally with clo-
farabine at 8:00 AM, 12:00 noon, 8:00 PM and 12:00 midnight,
respectively. Various doses (600, 480, 384, 307, 246 mg/kg)
were adopted for every time point. After 7 days continuous
administration, the Bliss method was used to calculate
LD50s of clofarabine at four different dosing-time points in a
24-hour period.
Subacute toxicity assay
One-hundred twenty mice were divided into two equal
groups: 12:00 noon and 12:00 midnight administration
groups respectively. Each group was then divided into three
subgroups according to which treatment cycle they received
(5, 10 and 15 days). Treated animals received an intraperi-
toneal injection of clofarabine at a dose of 50 mg/kg daily
according to the predetermined arrangement. The same
numbers of mice served as vehicle controls for each treat-
ment group, and received the same volume of saline. During
the observation period, the mice were observed intensely
for food intakes, weight changes and abnormal reactions. By
the end of the assay, the blood of the mice was collected
into clean test tubes through the fossa orbitalis vein. A
portion of the blood was treated by EDTA for the whole
blood cell count, and another portion was used to separate
serum for further biochemical analyses. Then all the animals
were sacrificed. Main organs were promptly removed,
weighed, and fixed in 10% formalin for histopathological
examinations. Organ indexes of mice were assessed by the
ratio of organweight versus body weight (mg/10 g body wt.).
Sampling of plasma for pharmacokinetic assay
Mice were randomly divided into 14 groups (n Z 8). Seven
groups were injected intraperitoneally with 20 mg/kg of
Figure 1. Circadian rhythm of mortality rate of clofarabine
in mice.
Chronotoxicity of clofarabine in mice 229clofarabine at 12:00 noon and another seven groups were
treated at 12:00 midnight. The blood of the mice was
collected into clean test tubes with heparin sodium through
the fossa orbitalis vein at 0.5, 1, 1.5, 2, 4, 6 and 8 hours
after administration. The whole blood was centrifuged at
3000 rpm for 5 minutes to separate plasma, and obtained
samples were kept at 20C until analysis.
HPLC analytical conditions
The quantitative analysis of clofarabine in the mouse
plasma was performed on a 1100 HPLC system coupled with
a UV detector (Agilent, Palo Alto, California, USA). The
analytes were separated by a Symmetry SB-C18 column
(250 mm  4.6 mm, 5 mm, Waters, Milford, Massachusetts,
USA), and the mobile phase was comprised of acetonitrile
and acidized water (by ethylic acid at pHZ 4.0) at the ratio
of 16: 84. Other analysis parameters were as follows:
detection wavelength, 263 nm; flow-rate 1.2 mL/min, col-
umn temperature, 35C.
Preparation of calibration curves
Various amounts of clofarabine stock solution were spiked
into blank mouse plasma to afford a serial of standard so-
lutions, and the final concentrations were 0.05, 0.1, 0.5,
2.5, 5 and 10 mg/mL. A 200-mL volume of 7% perchloric acid
was added into an equal amount of sample, and vortexed
for 1 minute to precipitate protein. The mixture was then
centrifuged at 8000 rpm for 10 minutes at 4C. A 20-mL
volume of supernatant was collected and injected into
HPLC for quantitative analysis. The calibration curve and
corresponding equation were deduced from the area of
chromatographic peaks versus the concentrations of clo-
farabine in standard solutions.
Pharmacokinetic analysis
Concentrations of clofarabine in the mouse plasma were
analyzed using the validated HPLC method and calculated
by the calibration equation. Pharmacokinetic parameters
of clofarabine at different dosing-time were analyzed using
DAS 2.0 pharmacokinetic program (Chinese Pharmacology
Society, Shanghai, China).
Statistical analysis
Results were expressed as mean  SD. Statistical differ-
ences among groups were evaluated by One-Way ANOVA
and Post Hoc tests using SPSS statistical analysis software
(version 14.0, Chicago, Illinois, USA).
Results
Acute toxicity of clofarabine fluctuated in diurnal
rhythms
Acute toxicity of clofarabine was dosing-time dependent.
Administration with the same dose at daytime caused a
higher mortality rate. The cosine equation of regressionmodel was Y Z 0.517 þ 0.125 cos (15/he185) (Figure 1).
The most severe toxicity was observed in the 12:00 noon
treatment group with a mortality rate of 65%, while that of
the 12:00 midnight treatment group was only 40%. An LD50
assay also validated the chronotoxicity feature of clofar-
abine. LD50s varied a lot among different dosing-times. The
exact result was summarized as: LD50s of 8:00 AM, 12:00
noon, 8:00 PM, 12:00 midnight were 333.59, 319.73, 362.58
and 366.92 mg/kg, respectively.Subacute toxicity of clofarabine also exhibited a
circadian rhythm
The periodical measurement of weight indicated that
treatment with clofarabine decreased the body weight of
mice (p < 0.01 compared with vehicle controls), and this
effect was sensitive to the dosing-time (Table 1). Loss of
weight in the 12:00 noon group was much more significant
than the 12:00 midnight group (p < 0.01). This result
showed that the effect of clofarabine on the metabolism of
mice was time-sensitive.
Organ indexes determination also revealed significant
impacts of clofarabine on mice (Table 2). Compared with
vehicle controls, hyperplasia of the heart was found in all
the treated animals (p < 0.01), while indexes of liver and
spleen were both reduced. Weights of the lungs and kidneys
were merely affected. These results at least partly sup-
ported the claim that clofarabine possessed hepatotoxicity
and immunosuppression activities. Comparing the two
treatment groups, it was found that the 12:00 noon group
showed a more severe inhibition of the spleen than the
12:00 midnight group (p < 0.05) (Table 2).
The whole blood count results found that all indices were
downregulated by clofarabine, especially levels of RBC (red
blood cell) andWBC (white blood cell) (Table 3). Biochemical
analyses revealed levels of ALT, AST and BUN increased
significantly in the mouse serum following the treatment
(p < 0.01, compared with vehicle controls) (Table 4).
Although clofarabine administered at different dosing-time
exerted similar effects on blood count and biochemical pa-
rameters, obvious differences can be noticed by comparing
the two treatment groups. The level ofWBC in the 12:00 noon
group was lower than the 12:00 midnight group (not signifi-
cantly), indicating more significant immunosuppression,
which was coincident with the inhibitory effect on the









22.5  1.2 33.9  0.9 10.5  1.1
12:00 noon
treatment
22.1  0.9 16.3  1.2* 6.7  0.9*
12:00 midnight
control
22.3  0.8 32.5  0.6 9.6  0.8
12:00 midnight
treatment
21.9  1.2 17.2  1.1* 5.2  1.0*,**
Values are presented as mean  SD, n Z 20.
* p < 0.01 vs. vehicle control group.
** p < 0.01 vs. 12:00 noon treatment group.
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serum was found in the daytime treatment group (p < 0.05,
compared with the night group), which suggested more se-
vere impairment of liver.
Clofarabine at a dose of 50 mg/kg caused the death of
mice from the 8th day following administration. Similar to
results from the acute toxicity assay, a higher mortality
rate was found in the 12:00 noon group with 50% of the
accumulative mortality by the end of assay, while the
mortality rate in the 12:00 midnight group was only 25%.
Histological examinations of the liver and spleen found
that there was no abnormal change in vehicle control mice,
but obvious organ impairments were found in both treat-
ment groups. Spotty necrosis and inflammatory cell infil-
tration were found in the livers from the treatment groups,
accompanied with excessive proliferation, hypertrophy,
and degeneration/necrosis of eosinophilic cells (Figure 2).Table 2 Effects of clofarabine on organ indexes of mice.
Groups Heart Liver
12:00 noon control 54  2 452  3
12:00 noon treatment 58  2** 412  3
12:00 midnight control 53  1 449  3
12:00 midnight treatment 60  1**,*** 430  2
Values are presented as mean  SD, n Z 20.
* p < 0.05 vs. vehicle control group.
** p < 0.01 vs. vehicle control group.
*** p < 0.05 vs. 12:00 noon treatment group.
Table 3 Effects of clofarabine on hematological parameters of
Groups RBC (1012/L) WB
12:00 noon control 9.5  1.5 10
12:00 noon treatment 7.2  1.4** 5
12:00 midnight control 9.6  1.7 9
12:00 midnight treatment 8.2  1.8 7
Values are presented as mean  SD, n Z 20.
* p < 0.05 vs. vehicle control group.
** p < 0.01 vs. vehicle control group.
*** p < 0.05 vs. 12:00 noon treatment group.
Hb Z hemoglobin; PLT Z platelet; RBC Z red blood cell; WBC Z whThe treatments also induced glomerular necrosis and
mineralization in spleens (Figure 3). All these abnormal
changes were time-dependent but not dosing-time sensi-
tive, in other words, increased dosing cycle aggravated
damages, but dosing-time exerted little effect on the
induced impairments.
Results of pharmacokinetic assay
The optimized HPLC analysis method was well employed in
the determination of clofarabine in the mouse plasma. The
analytes were separated well under the validated condi-
tions, and there was no endogenous interference observed
(Figure 4). Concentrations of clofarabine exhibited good
linearity versus the corresponding peak areas in the range
of 0.05e10 mg/mL. The linear equation for clofarabine
calibration was YZ 22.073X e 1.4845 (r2Z 0.9996, nZ 5).
Relative recovery rates from three quality control samples
at concentrations of 0.05, 0.5 and 5 mg/mL were 98.71%,
96.89% and 102.34%, respectively. The precision of the
method was evaluated by analyzing an identical sample
many times. The inter-day and intra-day precision were
6.56% and 4.18%, respectively, for the quality control
sample at a concentration of 0.5 mg/mL (n Z 5). These
results indicated that the employed quantitative method
was stable, and the obtained results were reliable.
Mean plasma concentration of clofarabine versus time
curve after a single intraperitoneal administration at a dose
of 20 mg/kg was illustrated in Figure 5, and fitted to the
two-compartment model well. No obvious difference
regarding the pharmacokinetic characters was found be-
tween the two treatment groups at different dosing-time,
and the main pharmacokinetic parameters were listed in
Table 5.Spleen Lung Kidney
2 46  14 121  30 138  16
0** 32  12* 112  35 130  30
5 45  15 124  24 140  21
4 41  8*** 109  21 135  22
mice.
C (109/L) Hb (g/L) PLT (109/L)
.2  0.8 144.6  26.5 300.0  116.2
.2  2.5** 126.4  30.2 265.4  102.8
.8  0.9 140.1  28.9 296.5  122.3
.3  3.6* 135.1  35.6 285.6  130.5
ite blood cell.
Table 4 Effects of clofarabine on liver and kidney functions of mice.
Groups ALT (U/L) AST (U/L) BUN (mmol/L) Cr (mmol/L)
12:00 noon control 38.5  4.5 134.2  7.5 24.1  3.4 26.1  4.7
12:00 noon treatment 55.4  7.2** 192.1  8.5** 42.2  8.5** 50.2  12.3**
12:00 midnight control 37.8  4.9 135.4  6.8 23.8  2.6 29.6  5.3
12:00 midnight treatment 50.3  4.8**,*** 186.4  4.8**,*** 39.5  5.1** 48.9  15.6**
Values are presented as mean  SD, n Z 20.
* p < 0.05 vs. vehicle control group.
** p < 0.01 vs. vehicle control group.
*** p < 0.05 vs. 12:00 noon treatment group.
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Circadian rhythms are essential for maintaining behavior,
endocrine, and other physiological activities in mammals,
which are largely influenced by feeding activities and
lightedark (LD) cycle. Importantly, this internal timekeeper
system is also involved in the absorption, distribution,
metabolism, and elimination of drugs in vivo [14]. As a
result, chronotherapy has been increasingly developed and
employed in cancer and other disease therapies [15]. Many
chemotherapy agents exhibit severe toxicity, such as bone
marrow suppression, liver and kidney dysfunction, gastro-
intestinal reactions and decreased immune function.
Although chronochemotherapy cannot avoid all these side
effects, it can minimize the unfavorable effects, and ach-
ieve a good efficacy. Numerous animal experiment studies
have demonstrated that the toxicity of drugs is significantlyFigure 2. Histological examination of livers from mice (H&E stain
(at 12:00 noon); (C) treated with clofarabine for 10 days (at 12:00
noon).changed when administrated at various time points. Clin-
ical evidences has also proven that optimal dosing-time in a
24-hour period can augment the therapeutic efficacy, in-
crease overall survival rates and reduce toxicity in cancer
patients [16e17]. Usually, toxicity in the daylight is less
than in darkness for humankind. That means rest phase
administration is accompanied by greater risks [18].
Clofarabine is a novel deoxyadenosine analogue, and has
been identified as a safe antitumor agent with lower
extramedullary toxicity [19]. It is widely used because of
the high therapeutic efficacy on leukemia. It also functions
as a potential versatile antitumor agent for improving the
poor prognosis of patients, especially for the elderly and
relapsed pediatric leukemia [19e21]. However, it still has
many unfavorable side effects which are sometimes fatal.
For example, clofarabine-treated patients might have more
severe infections due to strong inhibition on bone marrow,ing). (A) Normal control; (B) treated with clofarabine for 5 days
noon); and (D) treated with clofarabine for 15 days (at 12:00
Figure 3. Histological examination of kidneys from mice (H&E staining). (A) Normal control; (B) treated with clofarabine for
5 days (at 12:00 noon); (C) treated with clofarabine for 10 days (at 12:00 noon); and (D) treated with clofarabine for 15 days (at
12:00 noon).
232 J.-J. Luan et al.hematological toxicity and immunosuppression [20,22].
Kidney and liver injuries are also common because clofar-
abine is mainly renally excreted and decomposed by the
liver [23e27]. Clofarabine in combination with cytarabine
caused high toxicity and unacceptable mortality in elderly
AML patients in a phase II trial [28]. Hence, chronotherapy
of clofarabine might provide a reasonable option to mini-
mize the toxicity.
Firstly, we assessed the acute toxicity of clofarabine at
dose of 330 mg/kg. After a 7-day treatment, clofarabine
caused the death of mice in all experimental groups. As
expected, higher mortality rates were observed in daytime
treatment groups, while more animals survived in night
treatment groups. At this dose, the highest toxicity of
clofarabine was found at 12:00 noon and the mortality rate
was 65%. In contrast, mortality rate at 12:00 midnight was
only 40%. To further confirm the circadian rhythms of acuteFigure 4. Chromatograms of clofarabine. (A) Blank plasma; (B)
obtained from a mouse at 10 min after administration.toxicity, we assessed LD50s at four circadian time points.
Consistently, significant differences of LD50 were found at
various time points especially at 12:00 noon and 12:00
midnight. All these hinted that the toxicity of clofarabine
varied significantly during a 24-hour period. The rest and
activity phases are the most susceptible and tolerable time
for mice, respectively.
Under the treatment schedules, neurotoxicity can be
easily observed in the treated animals. Intakes and mobi-
lization of mice were suppressed 2e3 hours after adminis-
tration. Convulsion and tremor occurred before the death
of the mice, but the survived can recover from the adverse
reactions gradually. There was no significant damage
discovered on main organs except slight hemorrhage of
digestive tract.
To investigate the reasons contributing to the toxicity of
clofarabine in mice, we treated mice at a low dose for ablank plasma spiked with clofarabine; and (C) plasma sample
Figure 5. Mean plasma concentration vs. time curve of clo-
farabine in mice after a single intraperitoneal administration
at dose of 20 mg/kg (n Z 8).
Chronotoxicity of clofarabine in mice 233long period, and then examined its impact on organs and
hematological parameters. As predicted, by the end of the
assay, mortality of mice caused by clofarabine at daytime
treatment was much more than at night. Liver and spleen
weights decreased significantly, which might suggest sub-
stantial damage of the two organs. This assumption was
confirmed by the changes of biochemical parameters.
Increased levels of AST and ALT are indicators of liver
injury, and dysfunction of the spleen is usually reflected by
a rise in BUN. By comparing the two experimental groups, it
was revealed that impairments on liver and spleen were
more aggravated when administrated in the daylight.
Further histological examination found that liver and kid-
ney injuries induced by clofarabine were time-dependent
and the prolonged dosing cycle was followed by more se-
vere impairments. However, daytime administration did not
result in too many negative effects on organs in this assay.
Upon observation, we found clofarabine mainly induced
impairments on liver, spleen and nerves, and hepatotoxic-
ity and nephrotoxicity were greatly affected by dosing-
time, but histological examination did not provide suffi-
cient clues to clarify this phenomenon. By investigation on
the weight of organs and biochemical parameters, we
assumed that the chronotoxicity of clofarabine on liver and
spleen was via regulation of signaling pathways modulating
the metabolism, but further research is needed to identify
the underlying mechanisms.Table 5 Main pharmacokinetic parameters of clofarabine
on mice.
Parameters (unit) Dosing-time
12:00 noon 12:00 midnight
A 0.321 0.309
B 0.787 0.763
t1/2a (h) 0.356 0.348
t1/2b (h) 2.395 2.389
V1/F (L/kg) 28.37 29.24
CL/F (L/h/kg) 2.707 2.629
AUC(0-t) (mg/L per h) 6.124 6.03
K10 (1/h) 0.095 0.029
K12 (1/h) 0.255 0.243
K21 (1/h) 1.886 0.825
A and B mean slopes of the curve at two different time points.Over 60% of administered clofarabine is unchanged when
excreted via renal filtration in the urine [29], and meta-
bolism delay will affect the toxicity [27], which suggests
elimination of clofarabine determines its toxicity. There-
fore we carried out separate pharmacokinetic assays at two
typical time points. Importantly, there was no significant
pharmacokinetic difference between the two groups,
hinting that the pharmacokinetic characteristics of clofar-
abine were not so sensitive to the dosing-time, and the
chronopharmacokinetics could not be a trigger to its
chrontoxicity. Perhaps, like many other drugs, the feeding
schedule and the excretion of detoxificative substances of
the liver result in the chronotoxicity of clofarabine, which
is also relative to the chrono-effects on metabolism.Acknowledgments
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